The rapid development of mRNA therapeutics has expanded what is possible across vaccines, personalised medicine, and emerging therapies. Their promise lies in how quickly they can be developed, how easily they adapt to different targets, and their ability to tackle diseases that previously had no treatments. However, the manufacturing reality is more demanding. mRNA production is a multi-stage process that requires tight control, careful integration, and equipment that can respond quickly as processes evolve.  

At every stage, manufacturers are balancing flexibility with consistency. From plasmid preparation and in vitro transcription through purification, concentration, lipid nanoparticle formulation, and final fill, each operation introduces its own technical demands. The challenge is not simply producing mRNA; it is doing so reliably, cleanly, and at a scale that supports both current and future programmes.

The reality of mRNA manufacturing complexity 

mRNA manufacturing is not a single operation but a connected sequence of sensitive unit processes. Process performance in one step affects what follows, so poor integration can quickly create downstream bottlenecks. As programmes move from development into GMP production, manufacturers must manage contamination risk, protect product quality, and maintain consistent performance across batches.  

This becomes more difficult at scale. Facilities need to coordinate multiple technologies, support changing process requirements, and maintain control over a molecule that is highly susceptible to degradation and environmental variability. For many manufacturers, the operational challenge is no longer whether mRNA can be produced, but whether it can be produced with the speed the market demands, consistently across batches, and with the control clinicians expect.  

mRNA manufacturing stands apart because it involves a fast-moving, relatively new modality that is also extremely fragile. Unlike many traditional biologics, RNA is highly susceptible to degradation and contamination, so the process environment must be tightly controlled from end to end.  

mRNA production moves through several distinct steps: synthesis, purification, concentration, lipid nanoparticle formulation, and fill-finish, each with its own sensitivities-how the mixture behaves, how much shear stress it experiences, and whether materials interact. Facilities need to accommodate changes in scale, process improvements, and different product formats without requiring major redesign.  

Let’s be blunt: if you are treating RNA like a traditional protein, you are going to have a bad day. The molecule does not care about process assumptions.  

From an engineering perspective, that means prioritising containment and consistency. Reducing open handling, simplifying transfers, and improving process visibility all help balance speed with control, which is critical as mRNA moves from development into larger-scale production. Closed systems, single-use flow paths, and modular equipment setups are commonly used to limit exposure to RNases and reduce variability.  

A shift towards modular, single-use architectures 

To address these demands, the industry continues to move towards single-use technologies and modular process architectures. In mRNA manufacturing, these systems help reduce cleaning burdens, shorten changeover times, and support more flexible facility design. They also allow manufacturers to build around closed processing strategies that improve contamination control and simplify deployment.  

The value, however, is not in single-use technology alone; it comes from how well the systems are integrated. Modular skids that bring together in vitro transcription, chromatography, depth filtration, tangential flow filtration, lipid nanoparticle formulation, and final drug product processing can give manufacturers a more coherent process environment. Each unit can operate independently while still fitting into a broader automation and control strategy.  

Turning engineering into operational advantage 

When properly designed, modular single-use systems can shorten the path to production, support future expansion, and improve process visibility. They make it easier to qualify equipment, reconfigure process trains, and reduce manual intervention across the workflow.  

This matters because mRNA manufacturing rewards control. Faster setup, more consistent execution, and better integration between unit operations can help manufacturers reduce risk while staying responsive to programme changes. In a market where timelines are tight and product demands are evolving, that operational flexibility becomes a strategic advantage.  

Market and capacity context 

mRNA is no longer just about pandemic-scale vaccine supply. The real opportunity now lies in smaller, faster, more targeted therapies, from oncology to rare diseases, where manufacturers need capacity that can adapt quickly instead of running a single fixed, large-scale campaign. That is why flexible, smaller-footprint facilities matter. They reduce the barrier to entry, support faster tech transfer, and make it easier to switch between programmes without major infrastructure changes. The winning manufacturing model is increasingly the one that can launch faster, pivot faster, and remain efficient across multiple products and batch sizes.  

The pandemic taught us that mRNA can be scaled rapidly. But the real lesson is that most customers do not need pandemic-scale capacity; they need agility. One client put it clearly: “We do not want rigid and inflexible equipment. We want flexible, modular platforms that can deliver a faster return on investment.”  

A platform for what comes next 

As the mRNA pipeline expands, manufacturing systems will need to support more than simple scale. They will need to support diversity of product types, faster development cycles, and increased pressure on consistency and documentation. Facilities built around modular engineering, closed processing, and integrated control are better placed to meet these expectations.  

The direction of travel is clear. mRNA manufacturing is moving towards facilities that are more adaptable, more integrated, and easier to deploy. In that environment, engineering is not just a support function; it becomes a key part of how manufacturers reduce complexity, protect product quality, and create processes that are ready for what comes next.  

About CPi Biotech 

CPi Biotech is a leading independent manufacturer of single-use assemblies and advanced bioprocess skid systems for the biopharmaceutical industry. Guided by an open-architecture philosophy and supported by a proven track record of successful project delivery across Europe and North America, CPi designs and builds flexible bioprocess solutions tailored to customer workflows. CPi enables clients to reduce complexity, enhance process control, and seamlessly adapt systems as their processes evolve. Solving biotech complexity through single-use skid innovation is at the core of CPi Biotech.  

mRNA Projects 

CPi has delivered comprehensive suites of single-use bioprocess skids designed to support advanced drug product workflows, including in vitro transcription (IVT), chromatography, tangential flow filtration (TFF), lipid nanoparticle formulation, and final drug product processing.  

A recent RNA manufacturing suite for an international client featured:  

• Full compliance with strict GMP standards across all systems.  

• Integration of single-use technologies to minimise cleaning and validation requirements.

• Seamless compatibility with centralised automation and control platforms. 

• Accelerated delivery within a demanding project timeline.  

• Compact footprint with a focus on ergonomic design and operator accessibility.  

• A modular, scalable configuration to support critical process steps.  

• Bespoke design and build of each skid to meet the client’s exact specifications.

Reach out to us: Info@cpibiotech.com and check out our recent projects.